Global Liquid Biopsy Market Continues Upward Trajectory, Projected to Reach US$ 10,938.6 Million by 2033 at a 21.7% CAGR

Posted on 2024-04-26 by Future Market Insights in Healthcare, Pharmaceuticals // 0 Comments

Liquid Biopsy Market

The global liquid biopsy market is expected to experience a notable upswing, with industry estimates putting its value at US$10,938.6 million by 2033. Over the next ten years (2023–2033), a strong Compound Annual expansion Rate (CAGR) of 21.7% is expected to drive this substantial expansion.

A novel method for detecting and tracking cancer, liquid biopsy provides non-invasive, real-time evaluation of tumor-related biomarkers in biofluids like blood, urine, and cerebrospinal fluid. Liquid biopsy technologies are transforming cancer care by providing early detection, treatment response monitoring, and individualized treatment selection, as our understanding of cancer biology and molecular diagnostics continues to progress.

As of right now, tumor tissue serves as the gold standard for determining the kind and stage of cancer. Important parties are attempting to remove the present obstacles to its use in order to increase its potential applications in the future. Liquid biopsy techniques have also been shown in numerous studies to be a viable means of identifying cancer patients’ genetic profiles. The investigations take into account the reactions closely in order to track the course of treatment and identify any early signs of therapeutic resistance.

Your Insightful Report Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

The need for more individualized treatment choices has driven the usage of liquid biopsies in recent years. Liquid biopsy is becoming more and more popular since it is affordable and accessible in many labs, especially in developing nations. For example, liquid biopsy tests are available at a number of labs in

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.
The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.
In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.
In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.
CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.
By sample type, blood sample type holds prominence in the liquid biopsy market.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1396

Key Developments by Liquid Biopsy Market Players

QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.
Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.
Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).
Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled:

BIOCEPT, INC.
Qiagen N.V.
Trovagene, Inc
Janssen Global Services, LLC
MDxHealth SA
Natera, Inc
F. Hoffmann-La Roche Ltd
Silicon Biosystems
Pathway Genomics Corporation
Sysmex Corporation
Others

Key Segments Profiled in the Liquid Biopsy Industry Survey:

By Biomarker Type:

CTCs (Circulating Tumour Cells)
ctNA (Circulating tumor Nucleic Acids)
Exosomes

By Sample Type:

Blood Liquid Biopsy
Urine Liquid Biopsy
Other (Plasma, Saliva, CSF) Liquid Biopsy

By Application Type:

Liquid Biopsy for Lung Cancer
Liquid Biopsy for Gastrointestinal Cancer
Liquid Biopsy for Prostate Cancer
Liquid Biopsy for Breast Cancer
Liquid Biopsy for Colorectal Cancer
Liquid Biopsy for Leukemia

By Region:

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan
Japan
Middle East and Africa

Obtain In-Depth Market Insights: Purchase Now to Access:

https://www.futuremarketinsights.com/checkout/1396

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Matched content

Editor’s pick